Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the ...

Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...

NEW YORK/TOKYO -- Pfizer will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the drugmaker dropped its other similar treatment ...

Pfizer (PFE) discontinues Beqvez hemophilia B therapy developed with Roche (RHHBY) due to low demand, shifting focus to an ...

Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

Now that his adult sons manage their own hemophilia care, columnist Joe MacDonald wonders how he can best support them.

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

Altuvoct (efanesoctocog alfa) was approved in the U.K. as a treatment for patients with moderate or severe hemophilia A ages ...

The Ministry of Health and Population and the World Federation of Hemophilia have signed an agreement to provide free medication to patients with hemophilia, a genetic disorder that causes blood ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 14 February 2025, approved efanesoctocog alfa (brand name Altuvoct) to be ...